Pfizer added that once each country updates its labeling, Celebrex will be the first oral selective COX-2 inhibitor available in Europe to treat this form of arthritis. Pfizer said that ankylosing spondylitis affects up to 0.9% of Europeans.
Rory O’Connor, vice president, medical and regulatory affairs, Europe, said: “Celebrex now offers an effective and well-tolerated treatment, adding to physician and patient choice in managing this devastating disease.”